.png){kind=icon}
.png){kind=icon}
Return
Poor performance status associated with inferior tarlatamab outcomes in a large, multi-institution real world database of patients with 2L+ ES-SCLC
.png){kind=icon}
OA
AI
A
M
J
L
A
R
C
M
C
DOI：10.1016/j.cllc.2026.07.001.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Tarlatamab is approved for 2L+ extensive stage small cell lung cancer (ES-SCLC). In previously published retrospective studies, tarlatamab resulted in inferior survival compared to that observed in the DeLLphi-304 trial. To better understand real world outcomes with tarlatamab, we examined a much larger, multi-institutional dataset.
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.3
Papers:
2.4K
Citations:
4.5K
Organization
Cited Papers